New gel shows promise for shrinking painful skin tumors in rare genetic condition
Disease control
Completed
This study tested a gel called NFX-179 on skin tumors (cutaneous neurofibromas) in 199 adults with neurofibromatosis type 1. Participants applied the gel daily for 6 months to up to 10 tumors. The goal was to see if the gel safely shrinks the tumors. Results showed some tumors re…
Phase: PHASE2 • Sponsor: NFlection Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 10:26 UTC